financetom
Business
financetom
/
Business
/
Lumexa Imaging Q4 Loss Widens, Revenue Rises; Issues 2026 Adjusted EPS Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lumexa Imaging Q4 Loss Widens, Revenue Rises; Issues 2026 Adjusted EPS Guidance
Mar 26, 2026 3:54 AM

06:24 AM EDT, 03/26/2026 (MT Newswires) -- Lumexa Imaging ( LMRI ) reported a Q4 net loss Thursday of $0.38 per diluted share, widening from a loss of $0.36 a year earlier.

Revenue for the quarter ended Dec. 31 was $267.7 million, compared with $248 million a year earlier.

Analysts surveyed by FactSet expected $261.2 million.

For 2026, the company said it expects adjusted EPS of $0.71 to $0.77.

Lumexa Imaging ( LMRI ) also reiterated its consolidated revenue guidance of $1.05 billion to $1.10 billion for 2026. Analysts polled by FactSet expect $1.07 billion.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Inventronics Declared Special Dividend
Inventronics Declared Special Dividend
Jun 25, 2024
06:48 AM EDT, 06/25/2024 (MT Newswires) -- Inventronics Limited (IVX.V), a designer and manufacturer of enclosures for the telecommunications, cable, electric distribution, energy, and other industries in North America, overnight Monday announced that its Board of Directors has declared a special dividend of C$0.10 per common share to be paid in cash on July 11, 2024 to shareholders of record...
Novo Nordisk's Wegovy Weight-Loss Drug Gets Approval in China
Novo Nordisk's Wegovy Weight-Loss Drug Gets Approval in China
Jun 25, 2024
06:49 AM EDT, 06/25/2024 (MT Newswires) -- Novo Nordisk A/S ( NVO ) said Tuesday that its Wegovy weight loss weekly injectable drug has been approved in China for long-term weight management. The drug will initially be available to patients who have a body mass index that falls under the category of obese and have at least one weight-related comorbidity,...
TIMELINE-Microsoft's decades-long battle with EU antitrust regulators
TIMELINE-Microsoft's decades-long battle with EU antitrust regulators
Jun 25, 2024
June 25 (Reuters) - The European Commission on Tuesday charged Microsoft ( MSFT ) with illegally bundling its chat and video app Teams with its Office product. The following are events in Microsoft's ( MSFT ) relationship with EU antitrust regulators and ongoing investigations into its other businesses: 1998 - The European Commission opens an investigation into Microsoft ( MSFT...
Microsoft hit with EU antitrust charge over Teams app
Microsoft hit with EU antitrust charge over Teams app
Jun 25, 2024
BRUSSELS, June 25 (Reuters) - Microsoft ( MSFT ) faces a hefty antitrust fine after the European Commission on Tuesday accused it of illegally linking its chat and video app Teams with its Office product. Two decades after Microsoft's ( MSFT ) last EU fine, the EU competition watchdog's latest action was triggered by a 2020 complaint from rival workspace...
Copyright 2023-2026 - www.financetom.com All Rights Reserved